We have an excellent consortium comprised of world-class European scientists.

Our pan-European team provides us with all of the skills we will need to make our vaccine a reality.

iQur Ltd

The consortium is led by iQur Ltd who have been developing the tandem coreā„¢ technology since 2007. The intellectual property behind the vaccine platform was licensed from University of Leeds, who are also a partner in the Framework 7 programme.

The company's lead candidate programme is obviously influenza, however, several other tandem core based vaccines are also in development for targets such as malaria, Burkholderia and hepatitis A & B. The technology is such that a wide variety of targets of different vaccines can be made using this platform technology. Furthermore, the lessons learned during the development of a universal influenza vaccine will also apply to other tandem core based vaccines.

University of Leeds

[To be added]

University College London (UCL)

In line with its position at the forefront of European collaboration in science and technology, UCL has participated in over 650 EU Seventh Framework Programme (FP7) projects to date and is consistently ranked amongst the top 5 university participants in EU collaborative research worldwide (#1 in the UK).

The Department of Biochemical Engineering at University College London is a world-leading department in micro-scale development technology with application to the bioprocessing of novel vaccines and therapeutic proteins and the Institute for Liver and Digestive Health at the Division of Medicine has a long-standing interest and expertise in the immune responses to viral infections.

Latvian Biomedical Research and Study Centre

[To be added]

CRP Sante Luxembourg

[To be added]

Vall d'Hebron University Hospital, Barcelona

Vall d'Hebron University Hospital is one of the largest hospital complexes in Spain, and is reference for several highly complex tertiary procedures. With more than 1,100 beds for a reference population of 415,146 patients, the hospital includes almost all medical and surgical specialties, clinical support units, laboratories as well as teaching and research centers.

The Epidemiology and Preventive Medicine Department is primarily focused on epidemiology and prevention of infectious diseases, in both individual and population levels. It has been pioneer in the establishment of vaccination programs, supervising the staff vaccination and immunization of patients in special circumstances as immunosuppression, transplantation, prematurity, international travel and post-exposure situations. The research group has wide experience in clinical assays on immunogenicity, efficacy and safety of influenza and other vaccines.


3P  Biopharmaceuticals is a European-based Contract Development and Manufacturing Organization (CDMO) specialized in the Development and GMP Manufacture of biopharmaceutical and cell therapy products from early stages (POC,PC) up to clinical and commercial.

The Company offers an integral service for the development and manufacture of biopharmaceutical products from Microbial fermentation and Mammalian cell culture

Project specific customization of many manufacturing related services such as analytical method development, process validation, stability studies, formulation, advanced therapy services (cell therapy) and Master and Working cell bank generation, characterization and Storage can be offered.


  • Development of Bioprocesses and Manufacturing of Biologics (NEW BIOLOGICAL ENTITIES / BIOSIMILARS & BIOBETTERS):

- Recombinant proteins

- Fusion proteins

- Antibody fragments

- Monoclonal antibodies

- Vaccines...

  • Advanced therapies (Cell therapy) for non-GMP/ GMP processes.

 Manufacturing related services:

- Generation of expression systems

- Bacterial, yeast capabilities (up to 1000L)

- Mammalian capabilities (up to 2x200L)

- Analytics development/validation

-Comparability Studies

-Stability studies (preliminary, GMP, cell banks)        

-Cell bank manufacture and storage